Navigation Links
GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America
Date:3/9/2011

CHICAGO, March 9, 2011 /PRNewswire/ -- GlobalCare Clinical Trials, Ltd, (GlobalCare) today announced its expansion into Latin America. GlobalCare provides selected clinical study visits at convenient locations – such as in the home or alternate settings – for study patients to support phase I-IV trials in a variety of therapeutic areas, genomics and personalized medicine in all age groups. GlobalCare's patient-centric service model provides faster patient recruitment, better protocol compliance and higher retention rates, while helping to decrease the cycle of time to biopharmaceutical development and speed delivery of life-enhancing products to market for the benefit of patients worldwide.

Regulatory-compliant services provided by GlobalCare include: global project management; study drug administration; blood and other biologic sample collection; clinical assessments; patient training and education; device management; source documentation; and data collection. In addition, the company offers central and local out-patient pharmacy services including storage and distribution, compounding and dispensing, cold chain logistics, and sourcing of commercial products and devices.

Serving the Globe

GlobalCare provides services in over 20 countries and maintains a centrally managed network of multilingual country coordinators who are trained and certified on Good Clinical Practice/International Conference on Harmonization (GCP/ICH) guidelines and have in-depth knowledge of local medical practices and country cultural attitudes. The network is augmented by an extensive pool of over 20,000 qualified local traveling physicians and nurses in the United States, Canada, Australia, Europe, Israel, and now Latin America. GlobalCare's model enables patients to participate in clinical trials regardless of study duration; frequency of visits; disease state; distance to site; and/or family, work or community commitments by conducting study vis
'/>"/>

SOURCE GlobalCare Clinical Trials, Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... ALBANY, New York , July 31, 2014 /PRNewswire/ ... published by Transparency Market Research "Electrodes for Medical Devices ... Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, ... Share, Growth, Trends and Forecast, 2013 - 2019," the ... USD 633.6 million in 2012 and is estimated to ...
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Held at ... patients with an overview of the disease and its ... drug side effects, as well as updates on the ... to Dr. Sandy Srinivas for organizing this educational opportunity,” ... kidney cancer. “Sandy and her colleagues have put together ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Calif., Oct. 15 ... INKN ), an innovative nanotechnology company developing ... industry, medical diagnostics and sensors and biotechnology research ... its first product offering – the StemDisc450™, a ...
... NORWALK, Conn., Oct. 15 UBM Medica today announces ... ) from MediSpecialty.com, Inc.   OBGYN.net is ... and patients.  The site provides article-based and multimedia content ... online forums – some of which have been running ...
... CoreLab Partners, Inc , the global entity resulting ... in February of this year, has launched a full ... as it relates to Dual Energy X-Ray Absorptiometry ( ... that we have formally launched state-of-the-art imaging solutions to ...
Cached Biology Technology:Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 2Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 3Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 4UBM Medica Acquires Leading Online Community OBGYN.net 2UBM Medica Acquires Leading Online Community OBGYN.net 3CoreLab Partners Launches New DXA Imaging Service Offerings 2
(Date:8/1/2014)... Knowing what causes them at the molecular level is ... have created the most detailed map to date of ... blinding diseases, such as age-related macular degeneration. The high-resolution ... which supplies blood and oxygen to the outer retina, ... abundance of proteins in different areas of the choroid, ...
(Date:8/1/2014)... the conductive tissue through which plants transport carbohydrates and ... are capped at one end by a sieve plate ... turn form a network throughout a plant,s body. ... play an important role in carbon sequestration, yet so ... says Professor Yk Helariutta from the Institute of Biotechnology, ...
(Date:8/1/2014)... most diverse families in the ocean today -- marine ... more than 400 million years ago in the Silurian ... its modern members. This Geology study by ... on 25 July 2014, tracks the remarkable evolutionary expansion ... is origin, the Lucinidae family remained at very low ...
Breaking Biology News(10 mins):A map for eye disease 2Developmental regulation of important plant phloem components discovered 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... Since its discovery in the 18th century, cocaine has ... reward centres in low doses, cocaine is extremely addictive ... potent compound did not evolve to ensnare humans in ... cocaine is a powerful insect neurotoxin, protecting coca bushes ...
... WA This Christmas season, think twice about spending ... tree. The good, old-fashioned methodkeeping your tree in a ... keep your tree green and healthy. Researchers have determined ... trees; in fact, in several cases the chemical retardants ...
... LANSING, Mich. Diversity is valuable socially, economically and ... has found that growing more corn to produce ethanol ... of beneficial insects to control pests, a loss valued ... states studied (Michigan, Iowa, Minnesota and Wisconsin). "Corn ...
Cached Biology News:Honeybees succumb to cocaine's allure 2Flame retardants prove ineffective on fresh-cut Christmas trees 2Diverse landscapes are better: Policymakers urged to think broadly about biofuel crops 2
...
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: